Page 461 - Clinical Application of Mechanical Ventilation
P. 461

Pharmacotherapy for Mechanical Ventilation  427


                                             Adverse Effects. When inhaled, atropine is readily distributed throughout the body
                                             and may cause systemic effects such as tachycardia, nervousness, headache, and
                                             dried secretions. Atropine easily penetrates the blood-brain barrier and at higher
                                             levels may cause hallucination or mental confusion. Patients with atropine-induced
                                             hallucinations have been erroneously diagnosed with psychiatric disorders.
                                               Other anticholinergic agents such as ipratropium bromide (Atrovent) and glycopyr-
                                             rolate (Robinul, an atropine derivative) are not well absorbed systemically and, when
                                             inhaled, produce fewer adverse effects than those produced by atropine. Drying of
                                             secretions is an adverse effect of Atrovent, but it can be prevented by proper humidi-
                                             fication or systemic hydration.

                                             Clinical Considerations. Ipratropium bromide is not indicated for the initial treatment
                                             of acute episodes of bronchospasm where immediate response is required. These
                                             agents are commonly used in addition to the rapid-acting beta agonists. For ex-
                                             ample, ipratropium bromide is premixed with albuterol sulfate for MDI use (Com-
                                             bivent). The normal dosage is 2 puffs of this mixture QID.

                                             Xanthine Bronchodilators


                                             The third class of bronchodilators, the xanthines, include the drugs theophylline
                        xanthine bronchodilators:
                        Drugs that produce bronchodila-  and its salt form aminophylline. Theophylline is a stimulant found in tea leaves
                        tion by inhibiting phosphodies-  and is chemically related to other stimulants found in coffee and colas. Because
                        terase, an enzyme that inactivates
                        cyclic 3’5’ AMP (a substance   of the structural similarity of caffeine and theophylline, they share effects such as
                        that promotes bronchodilation).   tachycardia, central nervous stimulation (wakefulness), and diuresis (and potential
                        Examples are oral theophyl-
                        line (Theo-Dur, Slo-bid) and   for dysrhythmia). Caffeine is a xanthine that produces similar effects to theophyl-
                        aminophylline, a water-soluble   line but works through somewhat different mechanisms and therefore can have an
                        theophylline (Aminophyllin,
                        Somophyllin).        additive effect (caffeine is included in aminophylline solution).
                                               Xanthines are used for their relaxing effects on smooth muscles and ability to
                                             inhibit inflammation; however, be aware that in some individuals theophylline may
                            Pulmonologists often   aggravate bronchospasm because it can lower esophageal pressure, which may lead
                          refer to theophylline as “Dig-   to reflux. Clinically, the xanthines are considered to be less effective in acute bron-
                          (digitalis)for the diaphragm,”
                          meaning that what digoxin   chospasm than the beta agonists and are more useful in the management of inflam-
                          does for heart contractil-  mation associated with asthma and COPD. For individuals with carbon dioxide
                          ity, theophylline does for
                          diaphragm contracticility.  retention, xanthines improve ventilation by heightening carbon dioxide sensitivity
                                             in the central nervous system and enhancing diaphragmatic contractility.
                                               Water-soluble aminophylline is suitable for intravenous administration and may
                                             be indicated as an add-on therapy for acute bronchospasm (Cottrell et al., 1995).
                                             Table 13-5 lists the oral and intravenous xanthine bronchodilators. Theophylline’s
                                             ability to enhance diaphragm contractility and respiratory drive are of primary con-
                                             cern for COPD patients, but there is renewed interest in the drug for asthmatic
                                             patients, particularly for its potential to reduce airway inflammation.
                                             Mechanism of Action.  Multiple  theories  on  the  mechanism  of  theophylline  have
                                             been described. One generally accepted mechanism is that theophylline produces
                                             bronchodilation by inhibiting phosphodiesterase (PDE). Recall that PDE rapidly
                                             inactivates cyclic 3′5′ AMP, the substance that relaxes the airway smooth muscles






                        Copyright 2013 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s).
                      Editorial review has deemed that any suppressed content does not materially affect the overall learning experience. Cengage Learning reserves the right to remove additional content at any time if subsequent rights restrictions require it.
   456   457   458   459   460   461   462   463   464   465   466